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Purpose: To determine whether the efﬁcacy and safety achieved with monthly ranibizumab as treatment for
diabetic macular edema (DME) can be maintained with less-than-monthly treatment.
Design: Open-label extension (OLE) phase of randomized, sham-controlled phase III trials: RIDE
(NCT00473382) and RISE (NCT00473330).
Participants: Five hundred of 582 adults who completed the 36-month randomized core studies elected to
enter the OLE.
Methods: All patients participating in the OLE were eligible to receive 0.5 mg ranibizumab according to
predeﬁned re-treatment criteria: Treatment was administered when DME was identiﬁed by the investigator on
optical coherence tomography or when best-corrected visual acuity (BCVA) worsened by 5 Early Treatment
Diabetic Retinopathy Study letters versus month 36. Patients were observed at 30-, 60-, or 90-day intervals
depending on the need for treatment.
Main Outcome Measures: The incidence and severity of ocular and nonocular events, proportion of patients
with 15-letter best-corrected visual acuity (BCVA) gain from baseline, mean BCVA change from month 36 (ﬁnal
core study visit), mean central foveal thickness (CFT), and mean CFT change from month 36.
Results: A mean of 4.5 injections were administered over a mean follow-up of 14.1 months. Approximately
25% of patients did not require further treatment based on protocol-deﬁned re-treatment criteria. Mean BCVA
was sustained or improved in these patients through the end of follow-up. Approximately 75% of patients
received 1 criteria-based re-treatment; mean time to ﬁrst re-treatment was approximately 3 months after the last
masked-phase visit. Mean BCVA remained stable in re-treated patients; CFT was generally stable with a trend
toward slight thickening in all patients when mandatory monthly therapy was relaxed.
Conclusions: Vision gains achieved after 1 or 3 years of monthly ranibizumab therapy were maintained with a
marked reduction in treatment frequency; some patients required no additional treatment. These observations are
consistent with other studies evaluating induction followed by maintenance ranibizumab therapy for DME. Patients
whose treatment was deferred by 2 years (randomized initially to sham) did not ultimately achieve the same BCVA
gains as patients who received ranibizumab from baseline. Ranibizumab’s safety proﬁle in the OLE appeared similar
to that observed in the controlled core studies and other studies. Ophthalmology 2015;122:2504-2513 ª 2015 by
the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
*Supplemental material is available at www.aaojournal.org.The efﬁcacy of intravitreal ranibizumab as a therapy for
diabetic macular edema (DME) is now well established.
Multiple randomized, controlled clinical trials, including
DRCR.net Protocol I,1,2 RIDE and RISE,3,4 Ranibizumab
for Edema of the mAcula in Diabetes 2 (READ-2),5,6
RESOLVE,7 and RESTORE8 have demonstrated superior
visual outcomes with ranibizumab treatment compared
with sham injection, intravitreal steroid therapy, or
macular laser photocoagulation. In the RIDE and RISE
phase III studies, monthly intravitreal injection with 0.32504  2015 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Incor 0.5 mg ranibizumab for 24 months was superior to
sham injection (with optional macular laser) across all the
major outcomes assessed, including improvement in best-
corrected visual acuity (BCVA), measured as the mean
change from baseline or proportion of patients gaining 15
letters, and improvements in retinal anatomy as assessed
on optical coherence tomography (OCT), color fundus
photography, and ﬂuorescein angiography. In addition, pa-
tients randomized to ranibizumab experienced signiﬁcantly
higher rates of improvement in diabetic retinopathy (DR).
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ISSN 0161-6420/15
Boyer et al  Ranibizumab in DME: Phase III RIDE and RISE Trialsseverity and lower rates of worsening of DR, with fewer
eyes worsening to proliferative DR compared with patients
randomized to sham injections. Of note, patients initially
randomized to sham injection who crossed over to monthly
ranibizumab at month 24 did not experience the degree of
improvements after 12 monthly injections as those patients
randomized to ranibizumab from the beginning of the
study.9
Outcomes of these studies underscore the importance of
early diagnosis and initiation of anti-vascular endothelial
growth factor (VEGF) therapy for patients with DME to
achieve optimal visual and anatomic outcomes, as well as
potential modiﬁcation of the natural history of the under-
lying DR. In clinical practice, intravitreal ranibizumab has
become an important frontline DME therapy. Thus, it is
important to understand whether the efﬁcacy observed in
phase III studies is maintained in a long-term treatment
setting.
Several studies in patients with DME inform this topic
and show that less than monthly ranibizumab treatment in
patients with DME may be effective for maintenance of
vision and management of macular edema. For example, the
RESTORE and DRCR.net Protocol I studies showed that
after an initial period of intensive therapy, BCVA can be
maintained with a signiﬁcant decrease in treatment burden
in patients with DME using a protocol-speciﬁed re-treat-
ment algorithm.1,8,10 The design of the RIDE and RISE
open-label extension (OLE) studies allowed further explo-
ration of a less than monthly treatment strategy in patients
with DME after an initial monthly treatment phase.
The RIDE and RISE OLE was designed to determine if
the visual and anatomic beneﬁts achieved during the 36-
month monthly dosing period could be maintained while
offering a lower treatment and visit burden when appro-
priate for patients on an individual basis. Patients who
completed the 36-month masked phase of the study were
eligible to continue, at their option, in the OLE phase, which
consisted of a criteria-based pro re nata (PRN) treatment
strategy in which 0.5 mg ranibizumab was administered on
evidence of DME on OCT or visual acuity loss (5 Early
Treatment Diabetic Retinopathy Study [ETDRS] letters)
from month 36. This allowed a continued evaluation of the
ocular and nonocular safety of ranibizumab in patients with
DME and further study of whether criteria-based PRN
treatment could maintain the gains in visual acuity and
anatomic measures achieved with monthly treatment. In this
report, we describe the outcomes observed in the cohort of
500 patients who completed the phase III core studies and
enrolled in the OLE.Methods
Clinical Trial Design
RIDE (NCT00473382) and RISE (NCT00473330) were method-
ologically identical, randomized, phase III, double-masked,
shameinjection-controlled clinical trials of ranibizumab in pa-
tients with DME. The design, baseline patient characteristics, and
core efﬁcacy and safety outcomes of the trials have been
described.3,9 Study protocols were approved by institutional reviewboards and ethics committees, and participants provided written
informed consent.
Patients and Treatment
Patients who had not previously discontinued study drug treatment
and completed month 36 of RIDE or RISE were eligible for
participation in the OLE phase. All patients were eligible to receive
PRN 0.5 mg ranibizumab on the basis of predeﬁned re-treatment
criteria that assessed visual and anatomic stability. At each visit,
treatment was administered if there was evidence of DME on OCT
(evaluated by the investigator and deﬁned as the presence of
intraretinal ﬂuid or cysts, subretinal ﬂuid, or subretinal pigment
epithelium ﬂuid; there were no absolute macular or central subﬁeld
thickness criteria that mandated treatment) or if patients demon-
strated a decrease in BCVA of 5 ETDRS letters from the month
36 value (due to DME and not another cause). Because the OLE
study design was ﬁnalized and the study was carried out before the
US Food and Drug Administration (FDA) approval of 0.3 mg
monthly ranibizumab for patients with DME, the determination to
use the 0.5-mg dose was made on the basis of the efﬁcacy and
safety data in patients with DME that existed at the time, such as
the RESTORE study.1,8,11
A ﬂexible visit schedule was used, with per-protocol visits
every 30 (7) days for patients who had received a ranibizumab
injection during the last visit and extension of the interval at the
discretion of the evaluating physician to 60 (7) or 90 (7) days if
no treatment was given during the last visit. The month 48 visit was
mandatory for all patients participating in the OLE, regardless of
the scheduled visit interval, to provide for an annual assessment
from the month 36 visit. Follow-up was planned to end at month 60
from the original study baseline or 30 days after FDA approval of
ranibizumab for DME, whichever occurred ﬁrst. On FDA
approval, the trial ended, resulting in varying durations of follow-
up time for individual patients in the OLE phase.
Objectives
The objectives were to evaluate the long-term safety, tolerability,
and efﬁcacy of multiple intravitreal injections of 0.5 mg ranibi-
zumab administered using a criteria-based PRN treatment regimen.
The treatment criteria were designed to maintain the visual and
anatomic stability achieved in patients with DME during the RIDE
and RISE core studies, while allowing additional ﬂexibility in
dosing and ofﬁce visit intervals for patients achieving disease
stability.
Statistical Analysis
Data from the OLE phases of RIDE and RISE were pooled for
these analyses. Because of the variable follow-up time and patient
attrition during the OLE, descriptive statistics are provided based
on observed data. Efﬁcacy and safety analyses for the OLE phase
are presented with observed values and no imputation for missing
data. For key efﬁcacy measures, estimates and conﬁdence intervals
(CIs) are provided for continuous variables for each treatment
group. For binary variables, the proportion is provided from
baseline or from month 36 for each treatment group. All CIs were 2
sided and at the 95% level. Month 36 (ﬁnal scheduled visit in the
core study) was used as a baseline for calculations of change in
visual and anatomic parameters during the OLE. Key efﬁcacy re-
sults are also presented from core study baseline.
Efﬁcacy Assessments
Although all patients were eligible to receive 0.5 mg ranibizumab
PRN in the OLE, some efﬁcacy analyses are presented by prior2505
Table 2. Patient Disposition in the RIDE and RISE Open-Label Extension by Prior Treatment Group During Core Phase (Pooled Data)
Sham/Crossover Ranibizumab 0.3 mg Ranibizumab 0.5 mg
Enrollment at baseline 257 250 252
Patients completing month 36, n (%) 188 (73.2) 196 (78.4) 198 (78.6)
Patients enrolled in OLE, n (%) 165 (64.2) 172 (68.8) 163 (64.7)
Follow-up during OLE, mean (SD), mos 13.8 (5.4) 14.5 (5.4) 14.1 (5.8)
Patients receiving re-treatment in OLE, n (%) 121 (73.3) 130 (75.6) 128 (78.5)
Patients not receiving re-treatment in OLE, n (%) 44 (26.7) 42 (24.4) 35 (21.5)
OLE ¼ open-label extension; SD ¼ standard deviation.
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monthly 0.5 mg ranibizumab, prior monthly 0.3 mg ranibizumab,
and prior monthly 0.5 mg ranibizumab). Efﬁcacy assessments
included mean BCVA and central foveal thickness (CFT) by prior
treatment group in the core studies, mean BCVA and CFT change
from month 36 by prior treatment group, and mean BCVA and
CFT change from month 36 in patients treated during the OLE and
in those not requiring treatment based on stability criteria. Month
36 was used as a baseline for comparison of outcomes during the
OLE to determine the efﬁcacy of PRN 0.5 mg ranibizumab for
maintaining outcomes achieved at the end of the core studies.
The University of Wisconsin Fundus Photograph Reading
Center evaluated study eye macular OCT images from OLE visits
at months 42, 48, and 60, and early termination if applicable, as
prespeciﬁed in the protocol. The Reading Center also evaluated the
fundus photographs and ﬂuorescein angiograms taken at months 48
and 60. Changes in ETDRS DR severity score (DRSS) and the rate
of worsening to proliferative DR were assessed as previously
described.9
Progression of DR was comprehensively evaluated in a time-to-
event analysis of ﬁrst new proliferative diabetic retinopathy (PDR)
event using a composite outcome end point that included both
changes in DR severity on fundus photographs plus the occurrence
of clinically signiﬁcant adverse events (AEs) or procedures. A new
PDR event was deﬁned by the ﬁrst occurrence of (1) progression
from nonproliferative DR (DRSS <60) at baseline to PDR
(DRSS 60) at a later time point, (2) use of pan-retinal photo-
coagulation laser, (3) vitreous hemorrhage (AE or slit-lamp
grade 0 at baseline to >0 at a later time point), (4) cases iden-
tiﬁed by ophthalmoscopy, (5) use of vitrectomy for reasons
related to DR or its complications, (6) iris neovascularization
AE, or (7) retinal neovascularization AE.
Safety Assessments
Safety for all patients enrolled in the OLE was summarized for the
following outcome measures: incidence and severity of ocular and
nonocular AEs and serious adverse events (SAEs), and incidence
of deaths. In the OLE phase of the study, the population used for
safety analyses included all patients enrolled in the OLE. Safety
analysis results are summarized by prior treatment group in the
core studies.Results
Demographic and baseline characteristics were similar to the
baseline characteristics of the overall population enrolled in the
RIDE and RISE core studies and were well balanced among the 3
prior treatment groups (Table 1, available at www.aaojournal.org).
A total of 759 patients were originally randomized in the 2 core2506studies; 582 completed month 36, of whom 500 elected to enter
the OLE (Table 2). There did not seem to be meaningful
differences in the baseline characteristics of patients who did or
did not enroll in the OLE. Ranibizumab was approved for
treatment of DME in the United States on August 10, 2012, and
the per-protocol conclusion of the OLE occurred approximately
30 days later. The majority of the 211 patients (42.2% of those
enrolled in the OLE) who did not complete the month 48 visit
discontinued because of the conclusion of the study (n ¼ 160), and
the same was true of those who did not complete the month 60
visit. Few patients who entered the OLE were lost to follow-up by
month 48 (n ¼ 7) or month 60 (n ¼ 12). In the data collected up to
the point of study conclusion, the mean follow-up duration during
the OLE was 14.1 months (Fig 1A).
Overall, 24.2% of patients enrolled in the OLE continued to
meet visual and anatomic stability criteria, and thus did not require
any additional therapy with 0.5 mg ranibizumab during follow-up
to maintain the visual and anatomic gains achieved at the end of the
core studies (Fig 1B). The remaining 75.8% of patients received at
least 1 criteria-based injection in the OLE, with a mean of 2.5, 2.4,
and 2.1 months for the prior 0.5 mg ranibizumab, prior 0.3 mg
ranibizumab, and prior sham/crossover groups, respectively, from
month 36 to the ﬁrst open-label ranibizumab re-treatment. Per the
core study protocol, no injection was given to patients at the month
36 visit as part of the masked treatment phase, and month 36 in-
jections occurred only if patients met the PRN re-treatment cate-
gory; therefore, this corresponds to a 3.1- to 3.5-month interval
from the last injection administered during the core phase of RIDE
and RISE. Of 298 patients in the OLE who had at least 12 months
of additional follow-up from month 36, 58 (19.5%) maintained
vision with no further therapy.
Overall, an annualized rate of 3.8 ranibizumab injections was
administered during the OLE (mean of 4.5 injections over a mean
14.1 months of follow-up); among the subgroup of patients
requiring treatment, an annualized rate of 4.8 injections was given
(mean of 5.9 injections over a mean 14.6-month follow-up period).
In 30% of cases in which no injection was given at a visit, the
subsequent visit was extended beyond 30 days (Table 3, available
at www.aaojournal.org).Visual Acuity and Anatomic Outcomes
The mean change in BCVA from baseline during the core and
extension studies is presented in Figure 2. After the transition from
monthly to PRN therapy, mean BCVA gains achieved by patients
at the end of the core studies were maintained throughout
the extension study, with patients initially randomized to
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Figure 2. Pooled (RIDE and RISE) mean change from baseline in
best-corrected visual acuity (BCVA) among patients enrolled in the open-
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exposure in the pooled RIDE and RISE open-label extension (OLE) phase.
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functional outcomes compared with patients in the sham/
crossover group who had ranibizumab treatment deferred for 24
months. Because of the variable follow-up time in the OLE, the
data beyond month 54 became unstable because of the low number
of patients with follow-up beyond that point. The actual mean
BCVA during the core and extension studies (Fig 3, available at
www.aaojournal.org) showed similar results.
Month 36 (end of the core studies) was used as a new baseline
for assessing BCVA change after the transition to PRN therapy.
Among all patients entering the OLE, the mean BCVA change
from month 36 was within 5 ETDRS letters at all time points,
demonstrating the efﬁcacy of the PRN regimen for maintaining
visual outcomes in this study (Fig 4A). This remained true when
patients were analyzed by prior treatment group in the core
studies (Fig 4B). Furthermore, patients who met PRN stability
criteria and therefore did not require treatment with ranibizumab
during the OLE experienced a mean change in BCVA of þ1.9
letters from month 36 to month 48 (Fig 4C). Patients who
received at least 1 ranibizumab injection under the protocol-
speciﬁed criteria experienced a mean change of 1.0 letter over
this same time period. Likewise, CFT remained stable under the
PRN regimen, with a trend toward a small (<50 mm) increase in
retinal thickness for all patients after transitioning from monthly to
as-needed therapy (Fig 4DeF).The PRN regimen was effective for maintaining categoric vi-
sual acuity outcomes achieved with monthly therapy. Although not
all patients enrolled in the core studies enrolled in the extension, at
month 48, the proportion of patients in the extension who achieved
a 15 ETDRS letter visual gain from original baseline (day 0) was
similar to the proportions seen at month 36 for patients randomized
in the core studies (Table 4). Among patients enrolled in the OLE,
approximately 45%, 49%, and 20% of patients had gained 15
ETDRS letters from baseline at month 48 in the prior 0.5 mg
ranibizumab, prior 0.3 mg ranibizumab, and prior sham/crossover
groups, respectively. Among all patients enrolled in the core
study (not limited to only those who enrolled in the extension),
41%, 44%, and 21% of patients gained 15 ETDRS letters from
baseline at month 36 in the 0.5 mg ranibizumab, 0.3 mg
ranibizumab, and sham/crossover groups, respectively.
For patients enrolled in the OLE, approximately 65%, 64%, and
51% of patients achieved a Snellen equivalent of 20/40 or better at
month 48 in the prior 0.5 mg ranibizumab, prior 0.3 mg ranibizumab,
and prior sham/crossover groups, respectively. This was also similar
to the results seen atmonth 36 for the original study population: For all
patients enrolled in the core study (not limited to thosewho enrolled in
the extension), 59%, 59%, and 42% of patients reached a Snellen
equivalent of 20/40 or better at month 36 in the 0.5 mg ranibizumab,
0.3 mg ranibizumab, and sham/crossover groups, respectively.
Diabetic Retinopathy Severity
At the end of the 24-month sham-controlled phase of the RIDE and
RISE studies, the rates of 2- and 3-step DRSS improvement in
patients randomized to sham injections were 5.4% and 1.3%,
respectively,9 and the respective rates of 2- and 3-step DRSS
worsening were 9.6% and 5.0%. These rates represent the natural
history of 2- and 3-step DRSS improvement and worsening in
contemporaneous patients with DME not receiving ranibizumab
(treated only with macular laser when indicated). Under monthly
0.3 mg ranibizumab treatment, 37.6% and 13.2% of patients
achieved 2- and 3-step DRSS improvement, respectively,9
and 1.3% and 1.3% of patients experienced 2- and 3-step2507
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monthly ranibizumab injections, patients initially randomized to sham
injections showed 23.8% and 3.8% rates of 2- and 3-step DRSS
improvement, respectively, and the respective rates of2- and3-step
DRSSworseningwere 9.2%and 3.8%.12Amongpatients receiving 0.3
mg ranibizumab, 38.9% and 15.0% experienced 2- and 3-step
DRSS improvement, respectively, and 2.6% and 1.3% experienced
2- and 3-step DRSS worsening, respectively, at month 36.12
Given the substantial effect of monthly ranibizumab on
increasing the likelihood of DRSS improvement and decreasing the
likelihood of DRSS worsening, we also wanted to examine the
effect of initiating less-frequent therapy on DR severity. Of note,
PRN re-treatment criteria were not related to changes in DRSS.
Among patients with evaluable DR outcomes at month 48, under
the PRN regimen, 27.2% and 11.2% of patients from the prior 0.3
mg treatment group who continued in the OLE (n ¼ 125)
demonstrated 2- and 3-step DRSS improvement, respectively,2508and 2.4% and 1.6% experienced 2- and 3-step DRSS wors-
ening, respectively (Table 5). Similar efﬁcacy was noted with the
0.5 mg ranibizumab group (n ¼ 118).
A time-to-event analysis was used to assess time to develop-
ment of a new proliferative DR event (Fig 5), using the previously
reported composite methodology for assessing disease worsening
by this metric9 and as described earlier. Patients treated with
ranibizumab had a low rate of development of PDR in the OLE
phase. Patients originally randomized to ranibizumab had a lower
risk of developing a new PDR event compared with patients
originally randomized to sham over time through month 54.
Safety
Treatment with PRN 0.5 mg ranibizumab during the OLE was
generally well tolerated. Because the data were not controlled and
patients had variable treatment exposure and durations of
Table 4. Efﬁcacy Outcomes in the RIDE and RISE Open-Label Extension by Prior Treatment During the Core Studies
RIDE RISE
Sham/
Crossover
Ranibizumab
0.3 mg
Ranibizumab
0.5 mg
Sham/
Crossover
Ranibizumab
0.3 mg
Ranibizumab
0.5 mg
Month 48 BCVA change from
month 36, mean (95% CI),
ETDRS letters
2.6 (5.6 to
0.5)
0.9 (3.6 to
1.8)
0.6 (1.2 to
2.4)
1.3 (0.3 to
2.9)
1.7 (3.6 to
0.2)
0.8 (1.1 to
2.7)
Month 48 CFT change from month
36, mean (95% CI), mm
9.6 (18.4 to
37.6)
46.1 (2.6 to
94.8)
44.1 (16.1e
72.1)
29.6 (3.4e
55.7)
23.3 (7.7 to
54.3)
4.2 (17.1 to
25.4)
No. of patients in analysis
Month 24 130 125 127 127 125 125
Month 36 130 125 127 127 125 125
Month 48 34 39 39 48 62 56
% of patients with 15-letter gain from baseline at:
Month 24 12.3 33.6 45.7 18.1 44.8 39.2
Month 36 19.2 36.8 40.2 22.0 51.2 41.6
Month 48 17.6 48.7 41.0 22.9 50.0 48.2
% of patients with <15-letter loss from baseline at:
Month 24 91.5 98.4 96.1 89.8 97.6 97.6
Month 36 92.3 96.8 96.1 91.3 99.2 97.6
Month 48 94.1 97.4 97.4 97.9 100 100
% of patients achieving BCVA Snellen equivalent 20/40 at:
Month 24 34.6 54.4 62.2 37.8 60.0 63.2
Month 36 42.3 55.2 59.1 42.5 63.2 59.2
Month 48 47.1 64.1 56.4 54.2 62.9 73.2
BCVA ¼ best-corrected visual acuity; CFT ¼ central foveal thickness; CI ¼ conﬁdence interval; ETDRS ¼ Early Treatment Diabetic Retinopathy Study.
Months 24 and 36 are based on patients randomized in the core study. Month 48 is based on patients enrolled in the open-label extension (OLE) phase.
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from the safety data. Ocular AEs (Table 6, available at
www.aaojournal.org) were similar to those observed during the
core, sham-controlled studies through month 24. The most com-
mon ocular AEs in the study eye observed during the OLE were
macular edema, retinal hemorrhage, conjunctival hemorrhage,
vitreous ﬂoaters, eye pain, and cataract. Ocular AEs typically seen
in patients with DME, such as vitreous hemorrhage, were un-
common (<3% of patients during the OLE). Ocular SAEs in the
study eye occurred infrequently and were reported in 9 of 500
patients (1.8%). A small percentage (<3%) of ocular AEs were
reported as severe. Two of 500 patients withdrew from the study
because of AEs, 1 patient with retinal detachment and 1 patientTable 5. Patients in the RIDE and RISE Open-Label Extension with E
Severity Score Change from Baseline at Months 36 and 48 by Treat
Patients, n (%)
Month 36: End of Core Studies
Sham/Crossover
(n ¼ 123)
Ranibizumab
0.3 mg (n ¼ 124)
Ranibizum
0.5 mg (n ¼
DRSS Improvement
3 steps 7 (5.7) 22 (17.7) 22 (18.8
2 steps 36 (29.3) 57 (46.0) 52 (44.4
1 step 61 (49.6) 77 (62.1) 70 (59.8
DRSS Worsening
3 steps 4 (3.3) 1 (0.8%) 1 (0.9)
2 steps 10 (8.1) 2 (1.6%) 3 (2.6)
1 step 12 (9.8) 4 (3.2%) 4 (3.4)
*Patients enrolled in the open-label extension (OLE) with diabetic retinopathwith retinal hemorrhage and blindness. Overall, 2225 injections
were administered during the OLE, and no cases of endoph-
thalmitis were reported.
Systemic AEs observed during the OLE were also similar to
those observed during the core, sham-controlled studies through
month 24. Nonocular SAEs potentially related to VEGF inhibition
occurred in 8.4% of patients in the OLE (Table 7, available at
www.aaojournal.org). No increase in SAEs was noted among
patients who required re-treatment during the OLE versus those
who did not require re-treatment (Table 8). During the OLE, the
incidence of stroke in all patients enrolled was 2.2% and the
incidence of myocardial infarction was 2.4%. Eighteen deaths
occurred during the OLE; causes of death included cardiacarly Treatment Diabetic Retinopathy Study Diabetic Retinopathy
ment Group During the Core Studies (Pooled, Observed Data*)
Month 48: OLE Phase
ab
117)
Sham/Crossover
(n ¼ 124)
Ranibizumab
0.3 mg (n ¼ 125)
Ranibizumab
0.5 mg (n ¼ 118)
) 6 (4.8) 14 (11.2) 9 (7.6)
) 26 (21.0) 34 (27.2) 42 (35.6)
) 53 (42.7) 56 (44.8) 60 (50.8)
8 (6.5) 2 (1.6) 1 (0.8)
14 (11.3) 3 (2.4) 3 (2.5)
17 (13.7) 11 (8.8) 8 (6.8)
y (DR) outcomes at baseline and month 48.
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Months 
Control Phase Sham/0.5 mg
Crossover  
Open-Label
Extension
Sham/crossover 
0.3 mg RBZ 
0.5 mg RBZ 
163 161 158 157 154 152 150  148 147 143 142 140 138 132 124 105 79 62 35 
Sham/crossover 165 156 148 139 135 131 127  120 116 111 111 110 107 104 101 84 55 43 28 
0.3 mg RBZ 172 170 168 167 164 160 156 154 152 151 150 148 147 142 136 120 90 72 47 
0.5 mg RBZ 
Figure 5. Time to development of new proliferative diabetic retinopathy (PDR) event, pooled, observed data from RIDE and RISE among patients enrolled
in the open-label extension (OLE). New PDR event deﬁned by the ﬁrst occurrence of (1) progression from nonproliferative diabetic retinopathy (NPDR)
(DR severity score [DRSS] <60) at baseline to PDR (DRSS 60) at a later time point, (2) use of pan-retinal photocoagulation laser, (3) vitreous hem-
orrhage (adverse event [AE] or slit-lamp grade 0 at baseline to >0 at a later time point), (4) cases identiﬁed by ophthalmoscopy, (5) use of vitrectomy for any
reasons related to DR or its complications, (6) iris neovascularization AE, or (7) retinal neovascularization AE. A patient is no longer at risk once he or she
develops the ﬁrst PDR event. *Treatment during core study. RBZ ¼ ranibizumab.
Ophthalmology Volume 122, Number 12, December 2015conditions, multiorgan failure, aggravated renal failure, squamous
cell carcinoma of the lung, metastatic ovarian cancer, and
decubitus ulcer; in 2 patients the cause of death was unknown
(Table 9, available at www.aaojournal.org).Discussion
The OLE phase of RIDE and RISE showed that a criteria-
based PRN regimen effectively maintained the visual and
anatomic gains achieved with initial monthly ranibizumab,
including clinically signiﬁcant beneﬁts on DR severity. In
addition, to the extent that comparisons may be madeTable 8. Summary of Nonocular Serious Adverse Events Potentially R
Data for Patients Enrolled in the Open-Label Extension [OLE] Phas
Extension
Patients, n (%)
Received Treatment During OLE
Prior Sham/
Crossover
(n ¼ 120)
Prior RBZ
0.3 mg (n ¼ 131)
Prior
(
Any nonocular SAE 8 (6.7) 15 (11.5)
Any bleeding/hemorrhage SAE 1 (0.8) 6 (4.6)
CNS/cerebrovascular 1 (0.8) 5 (3.8)
Non-CNS 0 1 (0.8)
Congestive heart failure 4 (3.3) 5 (3.8)
Hypertension 1 (0.8) 2 (1.5)
Thromboembolic event
Arterial 3 (2.5) 9 (6.9)
Venous 0 0
CNS ¼ central nervous system; PRN ¼ pro re nata; RBZ ¼ ranibizumab; SAE
2510between the controlled and uncontrolled portions of the
study, the safety proﬁle of criteria-based re-treatment with
ranibizumab seems consistent with previous observations.
Overall, on the basis of the additional ranibizumab exposure
achieved in the RIDE and RISE OLE, the 0.5 mg ranibi-
zumab PRN regimen used here seemed to be generally well
tolerated in patients with DME, with similar types of AEs
reported as those observed in the RIDE and RISE core and
other studies.
The overall plateau of visual acuity improvement
continuing from the end of the core studies throughout the
OLE, as seen in Figure 2, illustrates 2 important points
relevant to real-world implementation of clinical trial data.elated to Vascular Endothelial Growth Factor Inhibition (Pooled
e) by Need for Criteria-Based Pro Re Nata Re-treatment During
Study
Not Treated During OLE
RBZ 0.5 mg
n ¼ 128)
Prior Sham/
Crossover
(n ¼ 44)
Prior RBZ
0.3 mg (n ¼ 42)
Prior RBZ
0.5 mg (n ¼ 35)
8 (6.3) 6 (13.6) 2 (4.8) 3 (8.6)
3 (2.3) 2 (4.5) 1 (2.4) 1 (2.9)
2 (1.6) 1 (2.3) 0 1 (2.9)
1 (0.8) 1 (2.3) 1 (2.4) 0
3 (2.3) 3 (6.8) 1 (2.4) 2 (5.7)
0 0 0 0
4 (3.1) 2 (4.5) 2 (4.8) 1 (2.9)
1 (0.8) 0 0 0
¼ serious adverse event.
Boyer et al  Ranibizumab in DME: Phase III RIDE and RISE TrialsFirst, mean BCVA remained stable for at least 1 year using
less than monthly ranibizumab. Patients were followed for a
mean 14.1 additional months after the completion of the
core studies, and a mean 4.5 injections were administered,
with approximately 25% of patients not requiring reinjection
during the OLE. This corresponds to a mean annualized rate
of 3.8 injections/year, a signiﬁcant reduction in treatment
burden relative to monthly therapy. Of note, the visit in-
terval was extended, and patients did not have to return
monthly unless they were treated at the previous visit. Visits
could be extended to 60- or 90-day intervals at the discretion
of the investigator; therefore, the maintenance of vision in
the OLE was possible with a decrease in visit burden.
Second, these data further speak to the impact of delayed
anti-VEGF therapy on visual acuity outcomes, a key
observation from the RIDE and RISE core studies that stems
from the study design. Patients randomized to the control
group in the core studies received 24 months of sham in-
jections and rescue laser therapy before initiating treatment
with ranibizumab; once these patients crossed over to active
therapy, their visual gains failed to achieve those of patients
who were randomized to active therapy from the start of the
core studies. With continued PRN therapy in the OLE, these
prior sham-treated patients maintained what visual gains
they had achieved with a year of monthly ranibizumab
therapy, but their overall mean improvement in BCVA
remained smaller than in those who had received earlier
treatment. This failure to reach the same level of improve-
ment could be due to delay in initiation of ranibizumab
therapy, due to retinal damage from more extensive focal
laser treatment compared with the group originally ran-
domized to ranibizumab (Table 2 in Brown et al4), or due to
a need for further monthly therapy before transitioning to as-
needed therapy; because the study was not speciﬁcally
designed to address outcomes of immediate versus delayed
ranibizumab therapy, it is not possible to address this point
with certainty. However, the overall outcome underscores
the importance of early anti-VEGF therapy in real-world
clinical practice for patients newly diagnosed with DME,
because early anti-VEGF therapy seems to result in the best
treatment outcomes and minimizes the need for tissue-
destructive therapies such as macular laser.
One limitation of the OLE study is the relatively limited
number of patients who reached the month 48 or later visits.
Although the mean follow-up period in the OLE was 14.1
months, 42.2% of patients did not complete the month 48
visit. However, this was due to conclusion of the study after
FDA approval of ranibizumab for treatment of DME and
not to loss to follow-up. Although this affected the
robustness of data after month 48, patients with longer
follow-up were not selected on the basis of their response to
drug or randomized treatment, but only by the time at which
they were enrolled in the original studies. We would
speculate that longer-term results for the entire group would
be similar to results for those who completed month 48,
based on the 4- and 5-year data from DRCR.net Protocol I,
which demonstrate generally similar results to the RIDE/
RISE OLE.13
These results are consistent with other studies that have
demonstrated the efﬁcacy of less than monthly ranibizumabfor patients with DME. For example, in the RESTORE
phase III trial, patients were randomized to treatment with
ranibizumab þ focal/grid laser photocoagulation or 1 of 2
sham control groups: sham intravitreal injections þ laser or
sham laserþ ranibizumab. After 3 consecutive loading doses,
0.5 mg ranibizumab was administered according to a criteria-
based PRN regimen. Stability criteria were deﬁned as Snellen
equivalent 20/20 for 2 visits or no further BCVA
improvement for 2 consecutive visits. During the 8-month
PRN phase, patients received approximately 4 ranibizumab
injections, and the visual and anatomic gains achieved with
initial monthly therapy in RESTORE were maintained with a
PRN regimen. The 12-month core phase of the RESTORE
study was followed by a 2-year extension study,10 with all
patients treated under the 0.5 mg ranibizumab criteria-based
PRN regimen. In the RESTORE extension, visual and
anatomic beneﬁts were also maintained with criteria-based
ranibizumab re-treatment. Taken together, the results of
the RIDE, RISE, and RESTORE OLEs (N ¼ 720 patients)
provide compelling evidence supporting the efﬁcacy of
criteria-based regimens for maintaining visual and anatomic
gains achieved with initial, intensive ranibizumab therapy in
DME. The efﬁcacy of less than monthly ranibizumab for
maintaining vision also has been demonstrated in the
DRCR.net Protocol I study.1 During years 4 and 5 of
Protocol I, patients in both the ranibizumab plus prompt
and deferred laser groups required very little additional
treatment (median 0e1 injections) to maintain vision gains
achieved. The estimated mean change in BCVA from
baseline was þ7.4 at 4 years and þ7.2 at 5 years for those
who received prompt laser treatment and þ9.4 letters
and þ9.8 letters, respectively, for those who received
deferred laser treatment.13
In addition to the maintenance of visual acuity beneﬁts, a
continued beneﬁt on DR severity was also observed in the
RIDE and RISE extensions. Clinically signiﬁcant im-
provements in DRSS and reduced rates of signiﬁcant DR
worsening were both observed in patients initially ran-
domized to monthly ranibizumab therapy compared with
patients randomized to sham.9 It was unclear whether these
improvements in DR severity would persist with reduced-
intensity therapy. We have now demonstrated that DR im-
provements continue to be observed with relaxation of
treatment intensity. After a 1- to 3-year period of monthly
ranibizumab injections, 21.0% to 35.6% of participants
in the RIDE and RISE OLE with DR outcomes at month
48 (1 year of less than monthly injections) experienced
a 2-step improvement in DRSS from baseline. These
data, along with the fact that many patients required no
additional therapy for DME (discussed further in the
next paragraph), suggest that anti-VEGF therapy may
modify the course of disease in patients with DR and
DME.
A key ﬁnding of the RIDE and RISE OLE was that
approximately 25% of patients continued to meet visual and
anatomic stability criteria without any further ranibizumab
treatment during the OLE period. This raises 2 important
issues: First, because these patients appear to have reached
disease stability with 1 or 3 years of monthly ranibizumab
injections, continued treatment of these patients under a2511
Ophthalmology Volume 122, Number 12, December 2015ﬁxed interval regimen may result in unnecessary interven-
tion. Therefore, an individualized PRN approach could offer
fewer treatments, decreasing burden on patients and pro-
viders. Second, the success of these patients raises questions
regarding the underlying pathophysiology of diabetic retinal
disease and the potential modiﬁcation of the disease course
through VEGF inhibition. What underlying physiologic
mechanisms might explain the difference between patients
who required no re-treatment and those who required some
re-treatment after the initial intensive anti-VEGF period? For
example, is it possible that retinal vascular inﬂammation or
levels of capillary nonperfusion are different in patients
whose disease is modiﬁed to the extent that no further ther-
apy is required? These questions cannot be easily addressed
by the current study, but provide tantalizing areas for
focusing additional research. Furthermore, it will be impor-
tant to explore the possibility of prospectively identifying
patients who do or do not require prolonged anti-VEGF
therapy; this will be useful not only for patient counseling
but also for designing future clinical trials in DR and DME.
In conclusion, the results of the RIDE and RISE OLE
provide further evidence for the efﬁcacy of a clinically rele-
vant ranibizumab treatment paradigm in DME: initial,
intensive therapy followed by observation and maintenance
therapy when indicated. Consistent results were observed
across anatomic and visual acuity outcomes. Finally, the long-
term visual outcomes of patients who received delayed-onset
therapy (patients initially randomized to sham) continue to
underscore the importance of appropriate screening for pa-
tients with DR, so that DMEmay be identiﬁed and treated at a
stage when the best outcomes are likely.
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Figure 3. Pooled (RIDE and RISE) mean best-corrected visual acuity
(BCVA) among patients enrolled in the open-label extension (OLE)
(observed data). ETDRS ¼ Early Treatment Diabetic Retinopathy Study;
PRN ¼ pro re nata; RBZ ¼ ranibizumab. *Data become unstable after
month 54 because of the low number of patients at that point. yTreatment
during core study.
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